Non-surgical treatment of hilar cholangiocarcinoma
| Autor: | Alba Fiorentino, Gianmarco Surico, Valentina Ferraro, Alessia Surgo, Fabrizio Acquafredda, Riccardo Memeo, Riccardo Inchingolo, Stavros Spiliopoulos, Letizia Laera, Stefania Marini, Nicola de’Angelis |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Interventional radiology
medicine.medical_specialty Chemotherapy Percutaneous Radiotherapy medicine.diagnostic_test business.industry medicine.medical_treatment Gastroenterology Cancer Minireviews Ablation Liver transplantation medicine.disease Bile duct cancer Cholangiocarcinoma Radiation therapy Klatskin tumor Liver Oncology Medicine Radiology business |
| Zdroj: | World Journal of Gastrointestinal Oncology |
| ISSN: | 1948-5204 |
| DOI: | 10.4251/wjgo.v13.i11.1696 |
| Popis: | Cancer of the biliary confluence also known as hilar cholangiocarcinoma (HC) or Klatskin tumor, is a rare type of neoplastic disease constituting approximately 40%-60% of intrahepatic malignancies, and 2% of all cancers. The prognosis is extremely poor and the majority of Klatskin tumors are deemed unresectable upon diagnosis. Most patients with unresectable bile duct cancer die within the first year after diagnosis, due to hepatic failure, and/or infectious complications secondary to biliary obstruction. Curative treatments include surgical resection and liver transplantation in highly selected patients. Nevertheless, very few patients are eligible for surgery or transplant at the time of diagnosis. For patients with unresectable HC, radiotherapy, chemotherapy, photodynamic therapy, and liver-directed minimally invasive procedures such as percutaneous image-guided ablation and intra-arterial chemoembolization are recommended treatment options. This review focuses on currently available treatment options for unresectable HC and discusses future perspectives that could optimize outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|